Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)

N/AActive Not RecruitingNCT05276388

IRCCS San Raffaele1,100 enrolled

Overview

Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)

The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.

Study Type

OBSERVATIONAL

Enrollment

1,100

Conditions

Coronavirus Infections

Interventions

biological bankOTHER

biological bank of subjects vaccinated against SARS-CoV-2 infection

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years * Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others * Signing of informed consent from January to March 2021 Exclusion Criteria: * none

Locations (1)

IRCCS Ospedale San Raffaele

Milan, Milano, Italy

Outcomes

Primary Outcomes

COVID-19 vaccines response

Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers

Time frame: from Day 1 of first vaccination up to 1 years after the last vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.